ALRN-6924 vs Kahalalide F
Head-to-head comparison of ALRN-6924 (ALRN-6924 dual MDM2/MDMX stapled p53 mimetic peptide) and Kahalalide F (Kahalalide F) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | ALRN-6924 | Kahalalide F |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | ALRN-6924 dual MDM2/MDMX stapled p53 mimetic peptide | Kahalalide F |
| Molecular Weight | N/A | 1111.3 Da |
| Half-Life | Hours to days depending on formulation | N/A |
| Amino Acids | N/A | N/A |
| Typical Dose | Varies by clinical protocol | 0.1-3 mg/m2 IV in early trials |
| Route | Intravenous/Subcutaneous | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 40 | 85 |
| Research Status | Clinical | Pre-clinical |
ALRN-6924 Benefits
- ✓p53 reactivation
- ✓dual MDM2/MDMX inhibition
- ✓protease resistance
- ✓tumor cell apoptosis
Kahalalide F Benefits
- ✓antineoplastic
- ✓pro-apoptotic
- ✓membrane-active
- ✓anti-proliferative
ALRN-6924 Dosing
Clinical trial protocol dosing|Intermittent administration|Research-only escalation
Kahalalide F Dosing
IV infusion in phase I oncology studies|dose escalation used in trials|preclinical nanomolar assays
ALRN-6924 Side Effects
- ⚠nausea
- ⚠fatigue
- ⚠myelosuppression
Kahalalide F Side Effects
- ⚠fatigue
- ⚠nausea
- ⚠transaminase elevation
Research Overview
ALRN-6924
ALRN-6924 is one of the best-known stapled peptide therapeutics and has advanced into human oncology studies. Literature shows that hydrocarbon stapling can improve target affinity, serum stability, and cellular activity for this p53-mimetic scaffold.
Kahalalide F
Kahalalide F was investigated in multiple preclinical and early clinical cancer studies because of its unusual membrane-disrupting and anti-tumor effects. Development highlighted the promise and limits of marine depsipeptides as oncology leads.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.